Title of article
Antifungal Chemotherapeutics
Author/Authors
Krcmery, Vladimir C. St Elizabeth University - School of Health Care - Department of Pharmacology, Slovakia
From page
125
To page
135
Abstract
This review addresses trends in outcome and risk factors for invasive fungal infections, current antifungal agents and new therapeutic strategies. Current prospects for new therapies rest upon caspofungin, the first of a new class of antifungal molecules, the echinocandins, and new extended-spectrum azoles, voriconazole, posaconazole and ravuconazole. Approval by the Food and Drug Administration of the USA and the European Medicine Agency was given in 2001–2002 to voriconazole and caspofungin. Voriconazole clearly demonstrated a decrease in mortality in invasive aspergillosis and fusariosis fungal infections.
Keywords
Antifungals , Azoles , Echinocandins , Fungal infections , Treatment strategies
Journal title
Medical Principles and Practice
Journal title
Medical Principles and Practice
Record number
2694382
Link To Document